Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.

Herr MM, Torka P, Zhang Y, Wallace PK, Tario JD Jr, Repasky EA, Chen GL, Ho CM, Balderman SR, Ross M, Paiva B, Hernandez-Ilizaliturri FJ, McCarthy PL, Hahn T.

Bone Marrow Transplant. 2019 Jun 21. doi: 10.1038/s41409-019-0591-4. [Epub ahead of print]

PMID:
31227776
2.

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.

Ochoa MC, Perez-Ruiz E, Minute L, Oñate C, Perez G, Rodriguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, Lopez-Botet M, Berraondo P, Melero I.

Oncoimmunology. 2019 Apr 13;8(7):1599636. doi: 10.1080/2162402X.2019.1599636. eCollection 2019.

PMID:
31143521
3.

Circulating microRNAs and Their Role in Multiple Myeloma.

Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM.

Noncoding RNA. 2019 May 2;5(2). pii: E37. doi: 10.3390/ncrna5020037. Review.

4.

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.

Lahuerta JJ, Jiménez-Ubieto A, Paiva B, Martínez-López J, González-Medina J, López-Anglada L, Cedena MT, Puig N, Oriol A, Blanchard MJ, Ríos R, Martin J, Martínez R, Sureda A, Hernández MT, de la Rubia J, Krsnik I, Cabañas V, Palomera L, Bargay J, Mateos MV, Rosiñol L, San Miguel JF, Blade J.

Blood. 2019 Jun 20;133(25):2664-2668. doi: 10.1182/blood.2019000671. Epub 2019 Apr 22.

PMID:
31010846
5.

Analysis of monocitary subpopulations in relation to cardiovascular risk factors.

Marcos Jubilar M, Orbe J, Roncal C, Fernández Montero A, Colina I, Rodil R, Rodriguez JA, Zabaleta A, Paiva B, Pastrana JC, Páramo JA.

Clin Investig Arterioscler. 2019 Jul - Aug;31(4):152-159. doi: 10.1016/j.arteri.2019.02.003. Epub 2019 Apr 6. English, Spanish.

PMID:
30967277
6.

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Nuñez-Córdoba JM, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Puig N, Oriol A, Paiva B, Bladé J, Lahuerta JJ, San Miguel JF.

Blood Cancer J. 2019 Mar 18;9(4):36. doi: 10.1038/s41408-019-0176-x.

7.

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel JFS.

Leukemia. 2019 Apr;33(4):1056. doi: 10.1038/s41375-019-0408-x.

PMID:
30846864
8.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J.

Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28.

PMID:
30819926
9.

Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response.

Agirre X, Meydan C, Jiang Y, Garate L, Doane AS, Li Z, Verma A, Paiva B, Martín-Subero JI, Elemento O, Mason CE, Prosper F, Melnick A.

Nat Commun. 2019 Feb 18;10(1):821. doi: 10.1038/s41467-019-08679-z.

10.

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B.

Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28.

PMID:
30692097
11.

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.

Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, Moreno C, Vidriales MB, Toboso DG, Cedena MT, Ocio EM, Lecumberri R, García de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Pérez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Prosper F, Martinez-Lopez J, Lecrevisse Q, Verde J, Mateos MV, Lahuerta JJ, Orfao A, San Miguel JF.

Leukemia. 2019 May;33(5):1256-1267. doi: 10.1038/s41375-018-0308-5. Epub 2018 Dec 12.

PMID:
30542145
12.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I.

Nat Med. 2018 Dec;24(12):1867-1876. doi: 10.1038/s41591-018-0269-2. Epub 2018 Dec 6.

PMID:
30523328
13.

How deep is the myeloma iceberg?

San-Miguel JF, Paiva B.

Blood. 2018 Dec 6;132(23):2424-2425. doi: 10.1182/blood-2018-10-878637. No abstract available.

PMID:
30523123
14.

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Jelinek T, Paiva B, Hajek R.

Front Immunol. 2018 Nov 16;9:2431. doi: 10.3389/fimmu.2018.02431. eCollection 2018. Review.

15.

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).

Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R.

Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25. No abstract available.

PMID:
30370955
16.
17.

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018.

18.

Flow Cytometry.

Gascue A, Merino J, Paiva B.

Hematol Oncol Clin North Am. 2018 Oct;32(5):765-775. doi: 10.1016/j.hoc.2018.05.004. Epub 2018 Jul 31. Review.

PMID:
30190016
19.
20.

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, Tsitsilonis O, Dimopoulos MA.

Blood Cancer J. 2018 May 24;8(5):46. doi: 10.1038/s41408-018-0086-3. No abstract available.

Supplemental Content

Loading ...
Support Center